Ingevity Swings to Profit in Q3, Narrows YTD Loss Amid Divestiture

TL;DR

**Ingevity's Q3 profit and reduced YTD losses, coupled with a strategic divestiture, signal a potential turnaround, making it a cautious buy for long-term investors.**

AI Summary

Ingevity Corp (NGVT) reported a net income of $43.5 million for the three months ended September 30, 2025, a significant improvement from a net loss of $107.2 million in the same period of 2024. However, for the nine months ended September 30, 2025, the company posted a net loss of $82.5 million, though this is a substantial reduction from the $446.9 million net loss in the prior year. Net sales remained relatively flat at $333.1 million for the quarter compared to $333.8 million in Q3 2024, and decreased to $912.5 million for the nine-month period from $936.8 million in 2024. The company recorded a goodwill impairment charge of $183.8 million for the nine months ended September 30, 2025, down from $306.6 million in the prior year. A key strategic change is the divestiture of its industrial specialties product line and CTO Refinery, classified as discontinued operations, expected to close by early 2026. This divestiture is anticipated to have a major effect on Ingevity's operations and results, streamlining its focus on Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.

Why It Matters

This filing reveals Ingevity's strategic pivot away from its industrial specialties and CTO refinery businesses, which could streamline operations and improve profitability for investors in the long run. The significant reduction in year-to-date net loss, from $446.9 million to $82.5 million, despite flat quarterly sales, suggests underlying operational improvements and a potential shift in competitive positioning within its core segments. Employees in the divested units face uncertainty, while customers of Ingevity's remaining Performance Materials, Performance Chemicals, and Advanced Polymer Technologies segments can expect a more focused product offering. The broader market will watch how this divestiture impacts Ingevity's debt and future growth trajectory in specialized chemicals.

Risk Assessment

Risk Level: medium — The company reported a goodwill impairment charge of $183.8 million for the nine months ended September 30, 2025, indicating potential overvaluation of past acquisitions. While net income improved in Q3 2025 to $43.5 million, the company still has a year-to-date net loss of $82.5 million, and total equity decreased from $195.2 million at December 31, 2024, to $138.1 million at September 30, 2025, suggesting ongoing financial pressures.

Analyst Insight

Investors should closely monitor the progress and financial impact of the industrial specialties and CTO refinery divestiture, as its successful completion by early 2026 is crucial for Ingevity's strategic refocus. Evaluate the company's ability to reduce its long-term debt, which stands at $1,158.5 million, and improve cash flow from operations, which was $234.1 million for the nine months ended September 30, 2025, to assess the sustainability of its financial recovery.

Financial Highlights

debt To Equity

N/A

revenue

$912.5M

operating Margin

N/A

total Assets

N/A

total Debt

$1,158.5M

net Income

$43.5M

eps

$1.18

gross Margin

15.2%

cash Position

N/A

revenue Growth

-2.6%

Revenue Breakdown

Key Numbers

• $43.5M — Net Income (Q3 2025) (Significant improvement from $107.2M net loss in Q3 2024.)
• $82.5M — Net Loss (YTD 2025) (Reduced from $446.9M net loss in YTD 2024.)
• $333.1M — Net Sales (Q3 2025) (Relatively flat compared to $333.8M in Q3 2024.)
• $912.5M — Net Sales (YTD 2025) (Decreased from $936.8M in YTD 2024.)
• $183.8M — Goodwill Impairment (YTD 2025) (Lower than $306.6M in YTD 2024, but still significant.)
• $1,158.5M — Long-term Debt (Sept 30, 2025) (A key liability to monitor post-divestiture.)
• $234.1M — Cash from Operations (YTD 2025) (Increased from $64.1M in YTD 2024, showing improved cash generation.)
• 35,964,032 — Shares Outstanding (Nov 3, 2025) (Relevant for per-share metrics.)

Key Players & Entities

• Ingevity Corporation (company) — registrant
• Mainstream Pine Products, LLC (company) — purchaser in divestiture
• New York Stock Exchange (regulator) — exchange where NGVT is listed
• SEC (regulator) — Securities and Exchange Commission
• FASB (regulator) — Financial Accounting Standards Board
• $43.5 million (dollar_amount) — Net income for Q3 2025
• $107.2 million (dollar_amount) — Net loss for Q3 2024
• $82.5 million (dollar_amount) — Net loss for nine months ended Sept 30, 2025
• $446.9 million (dollar_amount) — Net loss for nine months ended Sept 30, 2024
• $183.8 million (dollar_amount) — Goodwill impairment charge for nine months ended Sept 30, 2025

FAQ

Risk Factors

• Goodwill Impairment [medium — financial]: The company recorded a goodwill impairment charge of $183.8 million for the nine months ended September 30, 2025, a reduction from $306.6 million in the prior year. While reduced, this remains a significant charge impacting profitability.
• Divestiture of Business Segments [high — operational]: Ingevity is divesting its industrial specialties product line and CTO Refinery, classified as discontinued operations. This strategic shift, expected to close by early 2026, will significantly alter the company's operational footprint and financial results.
• Net Loss from Continuing Operations [high — financial]: Despite a Q3 2025 net income of $43.5 million, the company reported a net loss of $82.5 million for the nine months ended September 30, 2025. This is an improvement from the $446.9 million net loss in the prior year, but indicates ongoing profitability challenges.
• Interest Expense [medium — financial]: Interest expense, net was $18.4 million for Q3 2025 and $56.4 million for the nine months ended September 30, 2025. This represents a significant outflow, particularly given the net losses from continuing operations.
• Long-term Debt [high — financial]: The company has $1,158.5 million in long-term debt as of September 30, 2025. Managing this debt burden, especially in light of ongoing losses from continuing operations and the strategic divestiture, is a key financial risk.

Industry Context

Ingevity operates in the specialty chemicals sector, which is characterized by innovation, customer-specific solutions, and cyclical demand tied to end markets like automotive and construction. The company's strategic divestiture signals a move to focus on higher-growth, higher-margin segments within this competitive landscape.

Regulatory Implications

The divestiture of business lines may trigger regulatory reviews depending on the nature of the assets and the acquirer. Ongoing compliance with environmental, health, and safety regulations remains critical for Ingevity's core operations.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-09-30: End of Q3 and Nine-Month Period — Reporting period for the financial results discussed in the 10-Q, including net sales, net income/loss, and goodwill impairment.
• 2026-01-01: Expected Divestiture Closing — Anticipated completion of the sale of industrial specialties product line and CTO Refinery, marking a significant strategic shift for Ingevity.

Glossary

Goodwill Impairment Charge

A reduction in the carrying value of goodwill on the balance sheet when its fair value is determined to be less than its carrying amount. Goodwill arises from acquisitions. (A significant charge of $183.8 million in YTD 2025, indicating that the value of past acquisitions has decreased.)

Discontinued Operations

A component of a business that has been disposed of or is classified as held for sale, and whose operations and cash flows can be clearly distinguished from the rest of the company. (The industrial specialties product line and CTO Refinery are classified as discontinued operations due to the planned divestiture.)

Continuing Operations

The ongoing business activities of a company that are expected to continue into the future, as opposed to discontinued operations. (Net income/loss from continuing operations is a key indicator of the core business's profitability, which was a loss of $71.5 million YTD 2025.)

Gross Profit

Revenue minus the cost of goods sold. (Gross profit was $133.9 million for Q3 2025 and $373.7 million for YTD 2025, showing the profitability of the company's core products before operating expenses.)

Basic Earnings (Loss) Per Share

Net income or loss divided by the weighted-average number of outstanding common shares. (Indicates the profitability attributable to each outstanding share of common stock. Basic EPS was $1.20 for Q3 2025 and $(2.27) for YTD 2025.)

Year-Over-Year Comparison

Ingevity reported a significant improvement in net income for Q3 2025 ($43.5M vs. a $107.2M loss in Q3 2024), though the year-to-date net loss ($82.5M vs. $446.9M) persists. Net sales saw a slight decrease year-over-year for both the quarter and year-to-date periods. A notable reduction in goodwill impairment charges ($183.8M vs. $306.6M YTD) is positive, but the company is undergoing a major strategic divestiture of key business lines, which will reshape its future financial profile.

Key Financial Figures

• $0.01 — ange on which registered Common Stock ($0.01 par value) NGVT New York Stock Exchange

Filing Documents

• ngvt-20250930.htm (10-Q) — 2101KB
• ex102restatednon-employeed.htm (EX-10.2) — 14KB
• ex103-ngvtxamendedandresta.htm (EX-10.3) — 24KB
• ex311-q32025.htm (EX-31.1) — 10KB
• ex312-q32025.htm (EX-31.2) — 10KB
• ex321-q32025.htm (EX-32.1) — 4KB
• ex322-q32025.htm (EX-32.2) — 4KB
• ngvt-20250930_g1.jpg (GRAPHIC) — 143KB
• 0001653477-25-000127.txt ( ) — 12635KB
• ngvt-20250930.xsd (EX-101.SCH) — 65KB
• ngvt-20250930_cal.xml (EX-101.CAL) — 127KB
• ngvt-20250930_def.xml (EX-101.DEF) — 329KB
• ngvt-20250930_lab.xml (EX-101.LAB) — 781KB
• ngvt-20250930_pre.xml (EX-101.PRE) — 603KB
• ngvt-20250930_htm.xml (XML) — 2674KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 3

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Statements of Operations 3 Condensed Consolidated Statements of Comprehensive Income (Loss) 4 Condensed Consolidated Balance Sheets 5 Condensed Consolidated Statements of Cash Flows 6 Notes to the Condensed Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 34

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 51

Controls and Procedures

Item 4. Controls and Procedures 53

- OTHER INFORMATION

PART II - OTHER INFORMATION 54

Legal Proceedings

Item 1. Legal Proceedings 54

Risk Factors

Item 1A. Risk Factors 54

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 55

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 55

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 55

Other Information

Item 5. Other Information 55

Exhibits

Item 6. Exhibits 56

SIGNATURES

SIGNATURES 57 2

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS INGEVITY CORPORATION Condensed Consolidated Statements of Operations (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, In millions, except per share data 2025 2024 2025 2024 Net sales $ 333.1 $ 333.8 $ 912.5 $ 936.8 Cost of sales 199.2 202.2 538.8 571.9 Gross profit 133.9 131.6 373.7 364.9 Selling, general, and administrative expenses 44.1 37.9 129.6 119.5 Research and technical expenses 7.0 6.2 21.0 18.0 Restructuring and other (income) charges, net 1.0 3.3 10.1 8.3 Goodwill impairment charge — — 183.8 306.6 Acquisition-related costs — ( 0.1 ) — — Other (income) expense, net 1.2 6.5 9.5 7.8 Interest expense, net 18.4 23.8 56.4 69.3 Income (loss) from continuing operations before income taxes 62.2 54.0 ( 36.7 ) ( 164.6 ) Provision (benefit) for income taxes on continuing operations 21.4 6.5 34.8 ( 23.6 ) Net income (loss) from continuing operations 40.8 47.5 ( 71.5 ) ( 141.0 ) Income (loss) from discontinued operations, net of income taxes 2.7 ( 154.7 ) ( 11.0 ) ( 305.9 ) Net income (loss) $ 43.5 $ ( 107.2 ) $ ( 82.5 ) $ ( 446.9 ) Per share data Basic earnings (loss) per share from continuing operations $ 1.12 $ 1.31 $ ( 1.97 ) $ ( 3.88 ) Basic earnings (loss) per share from discontinued operations 0.08 ( 4.26 ) ( 0.30 ) ( 8.43 ) Basic earnings (loss) per share $ 1.20 $ ( 2.95 ) $ ( 2.27 ) $ ( 12.31 ) Diluted earnings (loss) per share from continuing operations $ 1.10 $ 1.30 $ ( 1.97 ) $ ( 3.88 ) Diluted earnings (loss) per share from discontinued operations 0.08 ( 4.24 ) ( 0.30 ) ( 8.43 ) Diluted earnings (loss) per share $ 1.18 $ ( 2.94 ) $ ( 2.27 ) $ ( 12.31 ) The accompanying notes are an integral part of these financial statements. 3 INGEVITY CORPORATION Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, In millions 2025 2024 2025 2024 Net income (loss) $ 43.5 $ ( 107.2 ) $ (